GABA Therapeutics is clinical-stage biopharmaceutical company developing GRX-917, a deuterated version of etifoxine, initially for the treatment of generalized anxiety disorder (or GAD). Etifoxine has the rapid onset of anxiolytic activity of benzodiazepines without their sedating, addicting, or respiratory significant impact on motor skills or cognition.

InnarisBio is a formulation technology company developing a sol-gel based, intranasal excipient technology to facilitate nose-to-brain (or N2B) delivery of certain compounds, starting with Salvinorin A. InnarisBio’s non-invasive, N2B delivery technology is designed to avoid systemic circulation and first-pass metabolism, both factors that may reduce safety risks, depending upon the API.

PsyProtix is a discovery-stage biopharmaceutical company that is developing compounds to treat specific subsets of treatment resistant depression (or TRD) patients that are characterized by mitochondrial dysfunction with the aim to improve patient outcomes through a precision psychiatry approach.

Recognify Life Sciences is a clinical-stage biopharmaceutical company developing RL-007 as a treatment against cognitive impairment associated with schizophrenia (or CIAS).

Perception Neuroscience is a clinical-stage biopharmaceutical company developing PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications, initially focused on treatment-resistant depression (or TRD).

ATAI Life Sciences NV is an international (Berlin and New York based) biotech company builder leveraging a decentralized, data-driven platform model with the aim of ultimately healing mental health disorders. As general counsel and corporate development lead, report directly to the CEO and responsible for establishing, building out and managing ATAI's international legal, intellectual property and corporate development functions.

Executive Team member reporting directly to the CEO, serve as the chief legal and business development representative for Axial. Spearhead Axial's corporate development, transactions and licensing efforts, responsible for establishing IP strategy and operations and ensure the growth of patent estate, and manage internal legal function and personnel, as well as external legal counsel on a global basis. Select accomplishments include:• Played instrumental role in securing $19M Series A and $35M Series B with top-tier venture investors, including Longwood Fund, Domain Associates, Seventure Partners and Taiho Ventures.• Secured core IP from Caltech on favorable terms, enabling Series A.• Broadened platform by negotiating $10M oncology collaboration and ROFN with Taiho Ventures.• Drove ≥ 35x growth in issued patents via prosecution, mining R&D, contributing as an inventor, and securing other assets via licenses/options with major academic and government partners.• Extended runway by identifying, negotiating and executing sublease at significant discount (< $15NNN), and by leading establishment of Australian subsidiary to recover ~40% of R&D budget.

Executive Team member reporting directly to the CEO, served as chief legal and business development representative for publicly traded (NASDAQ), international biotechnology company. Led OvaScience's global licensing and business development efforts, serving as primary transactional resource in structuring, negotiating and executing a broad range of strategic contracts with academia, industry and government parties. Oversaw and managed global IP estate, resulting in >60x growth in patent protection. Responsible for building out legal operations and compliance functions, managing internal corporate, compliance, contracts and IP legal team members, and managing external legal counsel and securities litigation efforts on a global basis. Partnered with CEO on specific regulatory initiatives, and with the CFO in the drafting and review of public filings (e.g., 10K, 10Q, 8K). Served support and/or leading role in various public and private financings which contributed in excess of $300m in gross proceeds to the company.

Reporting directly to the CEO, responsible for leading OvaScience’s licensing and business development efforts, managed the company’s global intellectual property portfolio, and served as the internal legal resource to all of OvaScience’s functional units (e.g. research and development, clinical, commercial, finance, IR/PR, etc.).

Reporting directly to the COO, was responsible for developing a wide-range of critical business strategies, such as devising commercial plans for OvaScience's initial product lines, monitoring and evaluating the competitive landscape, and helping to generate and refine domestic and foreign market penetration strategies. In addition, managed OvaScience's IP portfolio by establishing internal IP processes, assessing the patentability of internal research, examining potential licensing opportunities, and directing outside counsel on, and participating in, the prosecution of patents both nationally and internationally. Served as the internal legal counsel to the business, science and clinical teams by frequently performing varied ad hoc research and negotiating, drafting and reviewing diverse contracts that frequently arise (e.g. CDAs, MSAs, CTAs, Consulting Agreements, etc.). Consulted closely with senior management on OvaScience’s confidential business development strategy and implementation efforts.

Performed market, competitive intelligence, and legal research. Assisted with initial business plan creation and strategy formulation. Performed complex valuations on client companies using generally-accepted valuation methods. Conducted due diligence reviews for emerging medical device, pharmaceutical and healthcare service companies, including acting as principal due diligence analyst for the Medical Growth Fund. Assisted with the development and execution of client presentations to venture capital (VC) and angel investors. Supervised Associate team on various projects, including weekly transaction reports. Finally, conducted interviews as part of the hiring committee for Business Development Associates.

Digested appellate briefs and drafted bench memoranda for cases pending before the Eighth District. Participated in discussions with the Judge and law clerks regarding cases before the Court. Attended oral argument, trials, sentencings and hearings, gaining well-rounded insight into the legal system and oral advocacy.

Provided market research and consulted primarily healthcare service start-ups on business strategy. Prepared market and competitive research reports. Representative accomplishments include: (1) developed sales and marketing strategy that doubled gross income and client acquisition within 18 months; (2) researched and proposed corp. expansion plans that were subsequently adopted.

Researched potential new business ventures, created and edited high-level presentations to retain or acquire new assets for Mellon Global Securities Services' administration/custody business. Researched and analyzed prospective business deals. Played active role in completion of RFP process. Served directly under Shaun M. Flavin (Director of US Sales, GSS).

Generated a "wellness curriculum" designed to improve the health of medical school students with Drs. Theodore Parran and Christine Delos-Reyes. Independently examined prior, similar curricula by both course analysis and direct contact with directors and other thought leaders across the country. Synthesized this input, "branded" pre-existing components, and produced marketing media regarding this novel wellness curriculum.